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This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based 
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decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
20.05.20 SARS-CoV-2 
infection protects 
against 
rechallenge in 
rhesus macaques 
Science/ 
article 
Monkeys that had recovered from infection 
with the new coronavirus were protected 
from re-infection, although how long the 
protection lasts is unclear. 
17.05.20 Prioritisation of 
ICU Treatments 
for Critically Ill 
Patients in a 
COVID-19 
Pandemic With 
Scarce 
Resources 
Anaesthesia 
Critical Care & 
Pain 
Medicine/ 
Journal Pre-
proof 
 Prioritising both critical care 
initiation and continuation is 
paramount to save the greatest 
number of lives. It enables to 
allocate scarce resources in priority 
to those with the highest probability 
of benefiting from them. 
 Prioritisation schemes and their 
criteria are adjusted to the level of 
resource scarcity 
  
19.05.20 Medical Doctors 
Awareness, 
Perception, and 
Attitude towards 
preprints from 
medRxiv (not 
 Cross sectional, web-based study 
was conducted with the help of an 
online questionnaire and sent to 
doctors 
2 
COVID-19 in 
Bangladesh: A 
Cross sectional 
study 
peer-
reviewed)   
 Conclusion: The health authorities 
should take appropriate training 
measures to increase the 
awareness of the medical doctors 
along with providing sufficient 
amount of personal protective 
equipment for the medical doctors 
and supporting staff before 
deploying them in hospitals. 
  
18.05.2020 Psychiatric and 
neuropsychiatric 
presentations 
associated with 
severe 
coronavirus 
infections: a 
systematic review 
and meta-
analysis with 
comparison to the 
COVID-19 
pandemic  
The Lancet 
Psychiatry | 
Article 
 This SR/meta-analysis looks at the 
psychiatric and neuropsychiatric 
consequences of coronavirus 
infections in 3,550 patients 
hospitalised with SARS, MERS 
and COVID-19 
 If infection with SARS-CoV-2 
follows a similar course to that with 
SARS-CoV or MERS-CoV, most 
patients should recover without 
experiencing mental illness 
 SARS-CoV-2 might cause delirium 
in a significant proportion of 
patients in the acute stage 
 Clinicians should be aware of the 
possibility of depression, anxiety, 
fatigue, post-traumatic stress 
disorder, and rarer 
neuropsychiatric syndromes in the 
longer term 
18.05.2020 A clinical risk 
score to identify 
patients with 
Covid-19 at high 
risk of critical care 
admission or 
death : an 
observational 
cohort study 
The Lancet 
Infectious 
Diseases | 
SSRN 
Preprint 
 This observational cohort study of 
1,157 patients acutely admitted to 
two London hospitals identified 
predictors of critical care admission 
and death in people admitted to 
hospital with COVID-19 and 
positive SARS-CoV-2 swab results 
 These predictors were 
incorporated into a risk score that 
will inform clinical care and stratify 
patients for clinical trials 
15.05.2020 Risks and impact 
of angiotensin-
converting 
enzyme inhibitors 
or angiotensin-
receptor blockers 
Annals of 
Internal 
Medicine | A 
Living 
Systematic 
Review 
 High-certainty evidence suggest 
that ACEI or ARB use is not 
associated with more severe 
COVID-19 disease 
 Moderate-certainty evidence 
suggests no association between 
use of these medications and 
positive SARS-CoV-2 test results 
among symptomatic patients 
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on SARS-CoV-2 
infection in adults 
 It remains uncertain whether these 
medications increase the risk for 
mild or asymptomatic disease or 
are beneficial in COVID-19 
treatment 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Artic
le type 
Summary 
22.05.2020 COVID-19: Real-
time forecasts of 
confirmed cases, 
active cases, and 
health 
infrastructure 
requirements for 
India and its 
majorly affected 
States using the 
ARIMA model 
medRxiv| 
preprint (not 
peer 
reviewed) 
 This study forecasts the confirmed and 
active cases for C19 until June, using 
time series ARIMA model, and based 
on predicted active cases estimates 
required isolation beds, ICU beds and 
ventilators for C19 patients 
 Forecasts are 441,896 confirmed 
cases (95% CI 210,240 to 673,552), 
124,712 active cases (95% CI 68,481 
to 180,944) by the end of June 
 Estimates require 106,006 isolation 
beds (95% CI 58,209 to 153,802), 
12,471 ICU beds (95% CI 6,848 to 
18,094) and 6,236 ventilators (95% CI 
3,424 to 9,047) to accommodate this 
forecast 
 Authors suggest a Public-Private-
Partnership model in the health sector 
to accommodate C19 patients and 
reduce the burden on the Indian public 
healthcare system 
20.05.20 Preliminary 
evaluation of 
COVID-19 disease 
outcomes, test 
capacities and 
management 
approaches 
among African 
countries./URL 
preprint from 
medRxiv 
and bioRxiv 
(not peer 
reviewed) 
al/Article 
type 
 In this study, COVID-19 disease 
outcomes (confirmed cases, deaths 
and recoveries), testing capacities and 
disease management approaches 
among African countries were 
evaluated. 
 Egypt, South Africa, Morocco and 
Algeria were clustered as countries 
with highest values of COVID-19 
disease outcomes on the continent 
during the 75-day period of 
observation. 
 The study recommends that the 
approaches adopted by the African 
countries which achieved high 
4 
recovery rates from COVID-19 should 
be integrated into healthcare 
management plans for the disease 
across the continent even as the 
situation unfolds. 
20.05.20 Individual 
quarantine versus 
active monitoring 
of contacts for the 
mitigation of 
COVID-19: a 
modelling study 
The Lancet/ 
Article 
 Under what conditions can individual 
quarantine more effectively control 
COVID-19 than active monitoring? 
 This model highlights the urgent need 
for more data on the serial interval and 
the extent of presymptomatic 
transmission to make data-driven 
policy decisions regarding the cost–
benefit comparisons of individual 
quarantine versus active monitoring of 
contacts. To the extent that these 
interventions can be implemented, they 
can help mitigate the spread of SARS-
CoV-2. 
19.05.20 Temporal and 
spatial 
characteristics of 
the spread of 
COVID-19 in Rio 
de Janeiro state 
and city 
preprints 
from 
medRxiv 
(not peer-
reviewed) 
 Study analyses temporal and spatial 
characteristics of the spread of COVID-
19 in the municipalities of the state of 
Rio de Janeiro, based on open data 
published by the Health Departments 
of Governments of the State of RJ and 
the Municipality of Rio de Janeiro, from 
February 27 - April 27, 2020. 
 Results suggest that the initial stages 
of spreading the virus across the state 
occur exponentially, with specific 
regions with a higher concentration of 
rates of cases, deaths and recovered 
people. 
 Qualitative and quantitative results, 
point out that the regions with the 
highest income average per capita 
have higher rates of confirmed cases 
and recovered people, however, high 
lethality is found in places of low 
income per capita. 
 
19.05.20 COVID-19 
Epidemic Forecast 
in Different States 
of India using SIR 
Model 
preprints 
from 
medRxiv 
(not peer-
reviewed) 
 It is estimated that the epidemic curve 
flattening in India will start from the first 
week of July and epidemic may end in 
the third week of October with final 
epidemic size ~1,75,000. 
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 The epidemic in Kerala is in final phase 
and is expected to end by first week of 
June. 
 Maharashtra is severely affected 
where the ending phase of epidemic 
may occur in the second week of 
September with epidemic size of 
~55,000. The model indicates that the 
fast growth of infection in Punjab is 
from 27th April 2020 to 2nd June 2020, 
thereafter, curve flattening will start 
and the epidemic is expected to 
finished by the first week of July with 
the estimated number of ~3300 
infected people. The epidemic size of 
COVID-19 outbreak in Delhi, West 
Bengal, Gujrat, Tamil Nadu and 
Odisha can reach as large as 24,000, 
18,000, 16,000, 13,000 and 11,000, 
respectively, 
19.05.2020 Using a delay-
adjusted case 
fatality ratio to 
estimate under-
reporting 
CMMID | 
Real time 
report last 
update 
19.05.2020 
(not yet peer 
reviewed) 
 Estimates of the percentage of 
symptomatic COVID-19 cases in 
different countries using case fatality 
ratio estimates based on data from the 
ECDC, correcting for delays between 
confirmation-and-death 
18.05.2020 Susceptible supply 
limits the role of 
climate in the early 
SARS-CoV-2 
pandemic 
Science | 
Report 
Using a climate-dependent epidemic model 
to simulate the SARS-CoV-2 pandemic 
outputs suggests that while variations in 
weather may be important for endemic 
infections, during the pandemic stage of an 
emerging pathogen the climate drives only 
modest changes to pandemic size 
Results imply that both tropical and 
temperate locations should prepare for 
severe outbreaks of the diseases and that 
summertime temperatures will not effectively 
limit the spread of infection 
Climate maybe important in the longer term 
where endemic cycles of the disease will 
likely be tied to climate factors and seasonal 
peaks may vary with latitude 
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15.05.2020 Inferring change 
points in the 
spread of COVID-
19 reveals the 
effectiveness of 
interventions 
Science | 
Article 
This modelling approach allows detection 
and quantification of the effect of 
governmental interventions and forecasting 
future case number scenarios 
Analysis highlights the importance of the 
precise timing and magnitude of interventions 
for future case numbers and the importance 
of including the reporting delay between the 
date of infection and the date of the 
confirmed cases in the model 
The code is freely available and can be 
readily adapted to any country or region 
14.05.2020 The potential 
effects of 
widespread 
community 
transmission of 
SARS-CoV-2 
infection in the 
WHO African 
Region: a 
predictive model 
BMJ Global 
Health | pre-
print 
This predictive modelling study conducted by 
the WHO predicts that C19 will infect almost 
one-quarter of a billion people in Africa during 
the first year of the pandemic and 190,000 
are likely to die unless immediate measures 
are taken to control the spread of the virus 
Risk of exposure and transmission in the 
WHO African Region is lower than other 
areas of the world but an increase in hospital 
admissions and care needs and impacts on 
morbidity and mortality of other health 
conditions, will strain limited resources where 
health systems are not designed to mitigate 
against the implications of widespread 
community transmission of SARS-CoV-2 
Countries in the WHO African Region need to 
expand the capacity and especially of 
primary hospitals, including basic emergency 
care needs, to mitigate implication of 
widespread community spread of SARS-
CoV-2 
Infection Prevention and Control 
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Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
20.05.20 Is Nigeria really 
on top of COVID-
19? Message 
from effective 
reproduction 
number 
preprint from 
medRxiv and 
bioRxiv (not 
peer 
reviewed)  
Research shows that control measures are 
working but not effective enough to keep 
R(t) below one. Also, the estimated 
fractional reported symptomatic cases are 
between 10 to 50%. Our analysis has 
shown evidence that the existing control 
measures are not enough to end the 
epidemic and more stringent measures are 
needed. 
19.05.20 Work-related 
COVID-19 
transmission in 
six Asian 
countries/areas: 
A follow-up study 
Plos One/ 
Article 
Work-related transmission is considerable 
in early COVID-19 outbreaks, and the 
elevated risk of infection was not limited to 
HCW. Implementing 
preventive/surveillance strategies for high-
risk working populations is warranted. 
19.05.20 Assessment of 
service 
availability and 
Infection 
prevention 
measures in 
hospitals of 
Nepal during the 
transition phase 
of COVID-19 
case surge 
preprints from 
medRxiv (not 
peer-
reviewed) 
 Nepalese medical fraternity 
expressed concerns regarding 
public health strategies of 
government and hospital 
readiness in response to 
upgoing case surge.  
 Service availability and 
Infection prevention and control 
(IPC) status was assessed in 
110 hospitals situated across 
seven provinces via electronic 
survey sent out to the frontline 
clinicians 24th March- 7th April 
2020; one response per 
hospital was analyzed. 
 Findings alert the Nepalese 
and other governments to act 
early and proactively during 
health emergencies and not 
wait until the disease disrupts 
their health systems. 
15.05.2020 Risk factors for 
SARS-CoV-2 
among patients 
The Lancet 
Infectious 
 This observational study from 3802 
people tested for C19 (including 
587 positive tests) in the UK found 
that a positive SARS-CoV-2 test 
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in the Oxford 
Royal College of 
General 
Practitioners 
Research and 
Surveillance 
Centre primary 
care network: a 
cross-sectional 
study 
Diseases | 
Article 
result within a primary care cohort 
was associated with similar risk 
factors as observed for severe 
outcomes of C19 in hospital 
settings, except for smoking 
 This study provides evidence of 
sociodemographic factors 
associated with a positive test, 
including deprivation, population 
density, ethnicity, obesity and 
chronic kidney disease 
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
21.05.2020 Recombination 
potential of 
SARS-CoV-2 
and MERS-CoV 
iScience | 
SSRN 
 This study suggests that 
recombination between SARS-CoV-
2 and MERS-CoV RNA is possible  
 Public health laboratories in high-
risk areas should develop 
diagnostic capability for the 
detection of recombined 
coronaviruses in patient samples 
19.05.2020 Screening for 
COVID-19: 
Patient factors 
predicting 
positive PCR 
test 
Infection 
Control & 
Hospital 
Epidemiology | 
Article 
 The selection of patients for SARS-
CoV-2 screening remains 
challenging as many factors 
influence the decisions on which 
patients to screen, including test 
resources, test accuracy and local 
disease prevalence 
 Strategies are needed to best utilise 
testing resources 
 This retrospective study of patients 
screened between 12 March 2020 
to 26 March 2020 in the US found 
that exposure to confirmed SARS-
CoV-2 and recent travel were both 
significantly more predictive of a 
positive test than the presence of 
any symptoms suggesting a role for 
testing patients with these risk 
factors regardless of symptom 
presence 
9 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Hydroxychloroquine 
or chloroquine with 
or without a 
macrolide for the 
treatment of COVID-
19: a multinational 
registry analysis 
The Lancet | 
Article 
 This observational study of 
96,032 patients with C19, 14,888 
of whom were treated with 
hydroxychloroquine, 
chloroquine, or their combination 
with a macrolide, across six 
continents evaluated real-world 
evidence related to outcomes 
with the use of 
hydroxychloroquine or 
chloroquine in the absence of 
reported randomised trials  
 Although observational studies 
cannot fully account for 
unmeasured confounding factors 
no evidence of benefit of 
hydroxychloroquine or 
chloroquine when either used 
alone or with a macrolide was 
found and also potential harm 
(decreased in-hospital survival 
and an increased frequency of 
ventricular arrhythmias) with the 
use of hydroxychloroquine or 
chloroquine drug regimens (with 
or without macrolide) in 
hospitalised patients with C19 
 20.05.20  How to Discover 
Antiviral Drugs 
Quickly 
 The New 
England 
Journal of 
Medicine/ 
Article 
 Molecular-dynamics 
simulations together with 
virtual high-throughput 
screening provide a means 
of quick evaluation of 
existing drugs for antiviral 
activity. The authors explain 
how these methods serve in 
the quest for drugs to treat 
Covid-19. 
17.05.2020 What are the effects 
of convalescent 
plasma for people 
with COVID-19? 
Cochrane 
Clinical 
Answers 
 Reviewers identified two case 
studies and six small case series 
evaluating convalescent plasma 
for people with COVID-19 that 
included 32 participants 
 All evidence was rated as very 
low certainty with a lack of 
higher-quality studies  
 It remains unclear whether these 
results are related to 
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convalescent plasma therapy, to 
the underlying natural history of 
COVID-19, or to other 
concomitant treatments 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Safety, 
tolerability, and 
immunogenicity 
of a recombinant 
adenovirus type-
5 vectored 
COVID-19 
vaccine: a dose-
escalation, open-
label, non-
randomised, first-
in-human trial 
The Lancet | 
Article 
 This first-in-human trial showed that 
the Ad5 vectored COVID-19 
vaccine is tolerable and 
immunogenic in healthy adults at 28 
days post-vaccination.  
 Humoral responses against SARS-
CoV-2 peaked at day 28 post-
vaccination in healthy adults, and 
rapid specific T-cell responses were 
noted from day 14 post-vaccination 
 This study suggests there is 
potential for further investigation of 
this vaccine candidate 
 An ongoing phase 2 trial in 
China will provide more 
information on the safety and 
immunogenicity of this vaccine 
candidate 
20.05.2020 DNA vaccine 
protection 
against SARS-
CoV-2 in rhesus 
macaques 
Science | 
Article 
 DNA vaccine candidates expressing 
different forms of the SARS-CoV-2 
Spike (S) protein elicited 
neutralising antibody titres which 
correlated with protection against 
SARS-CoV-2 in nonhuman 
primates 
14.05.2020 Targets of T cell 
responses to 
SARS-CoV-2 
coronavirus in 
humans 
with  COVID-19 
disease and 
unexposed 
individuals 
Cell | Article 
 Understanding adaptive immunity to 
SARS-CoV-2 will help vaccine 
design and evaluation of candidate 
vaccines, understand C19 
pathogenesis and calibration of 
pandemic control measures 
 SARS-CoV-2-specific CD4+ T cells 
and antibody responses were 
observed in all C19 cases, and 
CD8+ T cell responses were 
observed in most  
 CD4+ T cell responses to spike, the 
main target of most vaccine efforts, 
were robust and correlated with the 
magnitude of the anti-SARS-CoV-2 
IgG and IgA titers 
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 Valuable targets for candidate 
vaccine development were 
identified along with distinct 
specificity patterns between C19 
cases and unexposed health 
controls 
 SARS-CoV-2 reactive CD4+ T cells 
were detected in approx. 40 to 60% 
of unexposed individuals 
suggesting pre-existing cross-
reactive T cell recognition between 
circulating ‘common cold’ 
coronavirus and SARS-CoV-2 
Indirect impact of COVID-19 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Prevalence of 
mental health 
problems 
during virus 
epidemics int 
eh general 
public, health 
care workers 
and 
survivors: a 
rapid review 
of the 
evidence 
medRxiv | 
Review (not 
peer 
reviewed) 
 A rapid review of mental health 
problems (MHP) prevalence rates 
published since 2000, during and after 
epidemics, including the general public, 
healthcare workers and survivors 
 Most original studies on MHP were 
conducted in China in the context of 
SARS-CoV-1, and reported anxiety, 
depression, post-traumatic stress 
symptoms/disorder, general psychiatric 
morbidity, and psychological symptoms 
 The MHP rates across studies, 
populations and epidemics vary 
substantially 
 Results call for the use of validated and 
standardised instruments, reference 
norms, and pre-post measurements to 
better understand the magnitude of the 
MHP during and after epidemics 
20.05.20 COVID-19 in 
Uganda: 
Predicting the 
impact of the 
disease and 
public health 
response on 
disease 
burden 
preprint from 
medRxiv and 
bioRxiv (not 
peer 
reviewed) 
 The results indicate that COVID-19 
impact on Uganda may be relatively 
light, while there is a high risk of a 
significant negative impact on other 
disease burden if the lockdown 
response to COVID-19 is prolonged.  
 The results are likely to extend to other 
sub-Saharan populations, underlining 
the importance of tailoring COVID-19 
responses according to population 
structure and potential disease 
vulnerabilities. 
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Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
22.05.2020 Chloroquine or 
hydroxychloroquine for COVID-19: 
why might they be hazardous? 
The Lancet | 
Comment 
Christian Funck-
Brentano 
Joe-Elie Salem 
22.05.2020 Children appear half as likely to 
catch COVID-19 as adults 
UCL | News  
21.05.2020 Covid-19 and the impact on 
gender and sexuality 
IDS | Opinion Susie Jolly 
21.05.2020 Survey suggests rising risk of food 
and nutrition insecurity in Addis 
Ababa, Ethiopia as COVID-19 
restrictions continue 
IFPRI | Blog Kalle Hirvonen 
Gashaw Tadesse 
Abate 
Alan De Brauw 
21.05.2020 The economic impact of Covid-19 
around the world: remittances, 
updated growth and poverty 
projections, and the reintroduction 
of Barter in Fiji 
CGD David Evans 
Amina Mendez 
Acosta 
20.05.2020 Coronavirus: everyone wins when 
patents are pooled 
Nature | Editorial  
20.05.20 Vitamin-D and COVID-19: do 
deficient risk a poorer outcome? 
  
The Lancet Diabetes 
and Endocrinology/ 
In Focus 
Fiona Mitchell 
19.05.20 Septic shock presentation in 
adolescents with COVID-19 
The Lancet Child & 
Adolescent Health/ 
Correspondence 
Cecilia Dallan, 
Fabrizio Romano, 
Johan Siebert, 
Sofia Politi, 
Laurence Lacroix, 
Cyril Sahyoun 
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18.05.20 How covid-19 is accelerating the 
threat of antimicrobial resistance 
BMJ/ Opinion Jeremy Hsu 
19.05.20 Coronavirus vaccine trials have 
delivered their first results — but 
their promise is still unclear 
Nature/ News Ewen Callaway 
21.05.20 Africa: Let's Prepare for a 
Marathon Struggle Against 
COVID-19 
  
All Africa Dr Chibuzo Okonta 
20.05.20 South Africa: Why Easing the 
Lockdown Threatens to Put 
Workers in South Africa At Risk  
All Africa   
21.05.20 South Africa: SAMRC Scientists 
Harvest Live Coronavirus for 
Validation of Test Kits 
All Africa   
21.05.20 South Sudan: Minister Makuei 
Tests Positive for COVID-19 
All Africa   
21.05.20 Africa: COVID-19 'Is an African 
Governance Crisis' 
All Africa   
20.05.20 Global solidarity with Africa is an 
imperative 
UN brief   
20.05.20 How Academic Health Systems 
Can Move Forward Once COVID-
19 Wanes 
JAMA/ viewpoint Steven D. Shapiro, 
Paul B. Rothman 
18.05.20 Better the drug you know: 
Commentary on “Daughton 2020, 
Natural experiment concept to 
accelerate the re-purposing of 
existing therapeutics for Covid-19” 
Global Epidemiology/ 
Commentary 
Alex Broadbent 
19.05.20 When does a major outbreak 
become a Public Health 
Lancet Infectious 
Diseases/ Comment 
David N Durrheim, 
14 
Emergency of International 
Concern? 
Laurence O Gostin, 
Keymanthri 
Moodley 
May 2020 Water, climate change, and 
COVID-19: prioritising those in 
water-stressed settings 
Lancet Planetary 
Health/ 
Correspondence 
Richard Armitage, 
Laura B Nellums 
May 2020 Shared sanitation and the spread 
of COVID-19: risks and next steps 
Lancet Planetary 
Health/ 
Correspondence 
Bethany A Caruso, 
Matthew C 
Freeman 
19.05.20 How environmental racism is 
fuelling the coronavirus pandemic 
Nature/ Comment Harriet A. 
Washington 
19.05.20 Tackle coronavirus in vulnerable 
communities 
Nature/ Editorial    
19.05.20 United Nations, World Health 
Organization Caution COVID-19 
Disruptions Could Foster Surge in 
Extra AIDS-Related Deaths  
JAMA Health Forum Joan Stephenson 
19.05.20 In the Face of the COVID-19 
Pandemic We Are Only as Strong 
as the Weakest of Us 
IPS/ opinion David Nabarro and 
Joe Colombano 
20.05.20 Kenya: Youth Emerge as COVID-
19 Superspreaders 
All Africa news   
19.05.20 WHO countries agree 'equitable 
and timely access' to coronavirus 
vaccine, 'comprehensive 
evaluation' of response 
UN news   
19.05.2020 Update on the ongoing Novel 
Coronavirus (COVID-19) Global 
Epidemic, Brief #18 
Africa CDC   
18.05.2020 Planning for a COVID-19 
vaccination program 
JAMA | Viewpoint Sarah Schaffer 
DeRoo 
15 
Natalie J. Pudalov 
Linda Y. Fu 
18.05.2020 What can psychiatrists learn from 
SARS and MERS outbreaks?  
The Lancet 
Psychiatry | 
Comment 
Iris E Sommer 
P Roberto Bakker 
18.05.2020 Somalia sees “massive” rise in 
FGM during lockdown and 
Ramadan 
All Africa | News Emma Batha 
15.05.2020 Wrong but useful – what Covid-19 
epidemiologic models can and 
cannot tell us 
NEJM | Perspective Ingra Holmdahl 
Caroline Buckee 
15.05.2020 Drug researchers pursue new 
lines of attack against COVID-19 
Nature Biotechnology 
| News 
Charlotte Harrison 
12.05.2020 Neglected refugees find 
themselves even more neglected 
during COVID-19 
African Arguments | 
Blog 
Lucy Hovil 
Vittorio Capici 
18.05.2020 Early data show Moderna Covid-
19 vaccine generates immune 
response 
Statnews | News Helen Branswell 
16.05.2020 Covid-19: Mental health services 
must be boosted to deal with 
“tsunami” of cases after lockdown 
BMJ | News Ingrid Torjesen 
15.05.2020 The sprint to solve coronavirus 
protein structures – and disarm 
them with drugs 
Nature | News 
feature 
Megan Scudellari 
15.05.2020 Reopening society and the need 
for real-time assessment of 
COVID-19 at the community level  
JAMA | Viewpoint Frederick J. Angulo 
Lyn Finelli 
David L. Swerdlow 
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15.05.2020 More harm than good? The net 
impact of COVID-19 policies is 
what matters for health 
CGD | Blog Damian Walker 
Y-Ling Chi 
Amanda Glassman 
Kalipso Chalkidou 
15.05.2020 Sex workers must not be forgotten 
in the COVID-19 response 
The Lancet | 
Comment 
Lucy Platt 
Jocelyn Elmes 
Luca Stevenson 
Victoria Holt 
Stephen Rolles 
Rachel Stuart 
14.05.2020 Recommendations from 
Guatemala to urban municipalities 
responding to COVID-19 in low- 
and middle-income countries 
ARISE | Blog Guillermo Hegel 
Yaimie Lopez 
Kim Ozano 
14.05.2020 Integrating implementation 
science into covid-19 response 
and recovery 
BMJ | Editorial Lisa Hirschhorn 
Justin D Smith 
Miriam F Frisch 
Agnes Binagwaho 
13.05.2020 How COVID-19 is changing the 
world: a statistical perspective 
from international agencies  
World Bank | Blog Haishan Fu 
13.05.2020 How nutrition can protect people’s 
health during COVID-19 
World Bank | blog Muhammad Ali 
Pate  
Martien van 
Nieuwkoop 
12.05.2020 Waste in covid-19 research BMJ | Editorial Paul P Glasziou 
Sharon Sanders 
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Tammy Hoffmann 
11.05.2020 COVID-19 and postinfection 
immunity 
JAMA | Viewpoint Robert D Kirkcaldy 
Brian A. King 
John T. Brooks 
29.04.2020 We need global health systems to 
be stronger than ever: corruption is 
getting in the way 
Health Systems 
Global | Blog 
Rachel Cooper 
 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
21.05.2020 Revealing the toll 
of COVID-19 
Prevent 
Epidemics | 
Tool 
 This technical package helps guide 
governments in rapid mortality 
surveillance, informing decision-
making based on the true impact of 
C19 within their countries 
May 2020 Key considerations 
for COVID-19 
management in 
marginalised 
populations in 
Southeast Asia: 
transnational 
migrants, informal 
workers, and 
people living in 
informal 
settlements 
SSHAP | 
Briefings 
 This brief presents considerations of 
C19 management among structurally 
vulnerable populations in SE Asia 
including transnational migrants, 
people working in the informal 
economy, and people living in 
informal urban and peri-urban 
settlements 
 These populations are poorly 
understood ignored or left out of 
formal policy 
 Whilst not a systematic study of C19 
control measures, does include 
information on alternative parallel, or 
informal responses that are relevant 
to C19 control in the region 
May 2020 Key 
considerations: 
Covid-19 in the 
context of conflict 
and displacement 
– Myanmar 
SSHAP | 
Briefing 
 This brief focuses on how the 
interplay between conflict, 
displacement and inter-communal 
tensions in Myanmar may influence 
disease control 
 The response to C19 must be 
sensitive and effective where there 
are social and political challenges 
and where trust in authorities 
imposing diseases control may be 
low 
18 
 A range of non-state actors must be 
factored into a public health 
response 
 20.05.20  Impact of COVID-
19 in Africa 
 UN Policy 
Brief 
 This policy brief takes a 
snapshot of immediate impacts 
of the pandemic on health, 
economies, peace, security, 
human rights and humanitarian 
assistance in Africa. 
12.05.2020 Guidance on 
community 
physical distancing 
during COVID-19 
pandemic 
Africa CDC | 
Guidance 
 Revised guidance 
accommodating new evidence 
May 2020 Responding to 
COVID-19 in 
Africa: Using data 
to find a balance 
Partnership 
for Evidence-
based 
response to 
COVID-19 
(PERC) | 
Report 
 A consortium of global public 
health organisations and private 
sector firms collected social, 
economic, epidemiological, 
population movement, and 
security data from AU Member 
States to help determine the 
acceptability, impact and 
effectiveness of public health 
and social measures for C19 
 These findings have been 
developed into actionable 
guidance for governments and 
policymakers 
 PERC is working with 
governments to mitigate 
unintended social and economic 
disruptions of interventions to 
control C19 
18.05.2020 Management of 
covid-19: A 
practical guideline 
for maternal and 
newborn health 
care providers in 
sub-Saharan 
Africa 
J Maternal-
Fetal & 
Neonatal 
Med | 
Guideline 
 This guideline prepares and 
equips clinicians working in the 
maternal and newborn sections 
in the sub-region to manage 
COVID-19 during pregnancy 
and childbirth 
 April 2020 Preserve essential 
health services 
GFF | series 
country briefs 
 These country briefs provide 
data and guidance for policy 
makers and practitioners on 
preserving essential health care 
services in a time of crisis to 
19 
during the COVID-
19 pandemic 
help sustain progress achieved 
over recent years 
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Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
04.06.2020 
12pm ET 
CGD Conversations 
on COVID-19 and 
Development: John 
Nkengasong 
Event  CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
24 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
  
 
25 
Suggested citation 
Millington, K.A. and Reddin, S. (2020). COVID-19 Health Evidence Summary No.45. K4D 
Evidence Summary. Brighton, UK: Institute of Development Studies. 
Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based on 3 hours of 
desk-based research each day. The summary is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to decision 
makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace 
medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any 
decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of 
leading organisations working in international development, led by the Institute of Development Studies (IDS), with 
Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, 
Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department 
(IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for International 
Development (DFID) and its partners in support of pro-poor programmes. It is licensed for 
non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any 
consequences arising from the use of information contained in this health evidence summary. 
Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other 
contributing organisation.   
© DFID - Crown copyright 2020. 
